Patient disposition Of the 471 patients randomized to tirzepatide 5 mg once weekly, 431 (91.5%) completed the study still receiving the study drug, with corresponding figures for the 10 mg and 15 mg once-weekly arms of 411/469 (87.6%) and 408/470 (86.8%), respectively, and 428/469 (91.3%) for the semaglutide arm
Your providers guidance and your personal response to the medication should drive the decision
It's widely used to support overall wellness, enhance energy, and strengthen immune function.R1 600,0030min RECOVERY IV TREATMENT This Recovery IV drip delivers fluids, electrolytes, essential vitamins, and nutrients directly into the bloodstream, bypassing the digestive system for rapid absorption
Zepbound (tirzepatide) is an FDA-approved dual GIP/GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight with weight-related comorbidities